If you or someone you know has been taking Reglan for a long time, you may be wondering about the risk of tardive dyskinesia. This involuntary movement disorder can persist even after stopping the medication. The transition from general awareness of medication risks to focused clinical guidance becomes critical when considering long-term use of drugs like metoclopramide. Here we discuss who needs closer monitoring and what the science says about risk factors.
Reglan (metoclopramide) is a dopamine D2-receptor blocking agent used to treat conditions such as gastroesophageal reflux and diabetic gastroparesis. However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Reglan, stating that metoclopramide can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning emphasizes that Reglan is contraindicated in patients with a history of TD and that the drug should be used for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks, and for those with diabetic gastroparesis, treatment should not exceed 12 weeks unless longer use is unavoidable, in which case routine monitoring for TD signs and symptoms is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, and extremities. The condition can be disfiguring and may persist even after discontinuation of the drug. Metoclopramide can also suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanism linking Reglan to TD involves its action as a dopamine D2-receptor antagonist, which can lead to extrapyramidal side effects, including TD (https://pubmed.ncbi.nlm.nih.gov/34712535/). While TD is more commonly associated with long-term use, cases have been reported after a single dose, particularly in patients with underlying risk factors (https://pubmed.ncbi.nlm.nih.gov/34712535/).
FDA adverse event reports from the FAERS database highlight the frequency of TD associated with Reglan. As of the most recent data, there were 5,712 reports of tardive dyskinesia, along with 3,268 reports of extrapyramidal disorder, 2,351 reports of dystonia, and 779 reports of dyskinesia (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:REGLAN). Other commonly reported events include nausea, vomiting, pain, fatigue, dyspnea, diarrhea, anxiety, asthenia, headache, tremor, dizziness, abdominal pain, depression, and death (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:REGLAN). The high number of TD reports underscores the seriousness of this adverse effect and the need for careful prescribing.
For patients in Texas who have developed TD after using Reglan, settlement considerations may arise. The adequacy of warnings regarding the risk of TD is a key factor. The FDA boxed warning clearly states the risk, but questions may remain about whether healthcare providers and patients were adequately informed, especially in cases where the drug was used for longer than recommended durations. The timeline between exposure and documented harm is also critical. TD can develop after weeks, months, or even years of use, and symptoms may appear after the drug is discontinued. In some cases, as reported in the medical literature, TD can occur after a single dose, particularly in patients with risk factors such as advanced age, female sex, or a history of extrapyramidal symptoms (https://pubmed.ncbi.nlm.nih.gov/34712535/). Patients affected by Reglan-induced TD may seek legal recourse through settlements. These settlements often consider the severity of the movement disorder, the duration of treatment, and the extent to which the patient was warned about the risk. The FDA's boxed warning serves as a benchmark for evaluating whether the manufacturer provided sufficient information. However, individual cases may vary, and legal outcomes depend on the specific circumstances of exposure and harm.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Reglan (metoclopramide) is a dopamine D2-receptor blocking agent used for gastrointestinal conditions. It carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder, as highlighted by an FDA boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk increases with longer treatment duration and higher cumulative doses.
Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, and extremities. It can be disfiguring and may persist even after stopping the drug. Metoclopramide can also suppress signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
FDA adverse event reports show 5,712 reports of tardive dyskinesia associated with Reglan, along with thousands of other extrapyramidal events (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:REGLAN). This underscores the seriousness of the risk.
Settlement considerations depend on the adequacy of warnings, duration of treatment, and severity of harm. The FDA boxed warning serves as a benchmark. Patients may seek legal recourse, and outcomes vary based on individual circumstances.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.